ASAhmed M. Soliman

Ahmed M. Soliman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmed M. Soliman has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Janus Kinase Inhibitors for Severe Alopecia Areata: A Systematic Literature Review and Network Meta-Analysis

    by Arash Mostaghimi, Ahmed M. Soliman, Benjamin Ungar, Sergio Vaño-Galvan, Jonathan J. Woolley, Kristen Westerhoff, Si-Tien Wang, Andreas Lazar, Henrique D. Teixeira, Steven Bhathal, et al.

  • Open Access

    Development of items to assess noticeability and sun sensitivity among patients with non-segmental vitiligo

    by David Rosmarin, Ahmed M. Soliman, Dana DiBenedetti, Amy Greenblatt, Rohini Sen, Stavonnie Patterson, Khaled Ezzedine

    Non-segmental vitiligo (NSV) is a chronic, progressive skin disease that manifests as bilateral skin depigmentation and is typically diagnosed by the age of 30 years [1–4]. The global prevalence of...

  • Open Access

    Economic Burden and Treatment Patterns Among Patients Diagnosed With Vitiligo in Japan: An Observational Retrospective Cohort Study

    by Naoki Oiso, Kent A. Hanson, Ahmed M. Soliman, Chao Li, Manabu Taura, Daniel Mercer, Andrew Rava, Danielle Bynoe, Haiyan Sun, Tamio Suzuki

    Vitiligo, a common and chronic depigmentation disorder, significantly impacts patients' quality of life and exerts a substantial economic burden. The deleterious impact of vitiligo can be exacerbated by comorbid conditions, including psychiatric and autoimmune conditions. Treatment may vary across geographic regions, and there is sparse evidence of treatment patterns for vitiligo in Japan. Evaluations of healthcare costs are also needed to help underline unmet needs, including data on the influence of comorbid conditions on costs. Here we report results of a retrospective cohort analysis using claims data from the Japan Medical Data Center database to evaluate the economic burden and treatment patterns among patients with vitiligo in Japan. Primary study outcomes were costs and healthcare resource utilization (HCRU) 12 months post‐index (diagnosis date) for patients with vitiligo versus matched controls, based on inpatient, outpatient, and pharmacy claims. In total, 28 800 patients were included (4800 in the vitiligo cohort; 24 000 matched controls). Patients with vitiligo had significantly greater all‐cause healthcare costs (¥84 766 vs. ¥55 011, p < 0.0001) and HCRU than matched controls, primarily driven by outpatient, dermatology‐, and vitiligo‐related procedure costs. In patients with vitiligo, comorbid psychiatric and autoimmune conditions significantly increased all‐cause healthcare costs versus no comorbid condition (¥193 468 vs. ¥78 313 and ¥185 179 vs. ¥77 184, respectively; both p < 0.0001). Most patients (67.5%) did not receive treatment for vitiligo in the 12 months following diagnosis. Of those who did, 76.0% received only phototherapy. Only 2.2% received second‐line treatment. Overall, Japanese patients with vitiligo face substantially higher healthcare costs and resource utilization than those without vitiligo, with burden further increased by psychiatric and autoimmune comorbidities; notably, most remained untreated in the year after diagnosis, and treated patients primarily received phototherapy.

  • Open Access

    Psychometric properties of the Vitiligo Noticeability Scale using data from a phase II randomized study of upadacitinib in adults with nonsegmental vitiligo

    by Khaled Ezzedine, Ahmed M Soliman, Mary Kate Ladd, Robin Pokrzywinski, Karin S Coyne, Rohini Sen, Bethanee J Schlosser, Jung Min Bae, Heidi S Camp, Iltefat Hamzavi

    The Vitiligo Noticeability Scale (VNS) is a patient-reported outcome that assesses treatment success. It was originally validated by measuring the cosmetic acceptability of a single target patch before and after treatment. We further investigated the psychometric properties of the VNS and determined if it could be used as a global measure of vitiligo noticeability by using in-trial data from a phase II randomized trial (NCT04927975) assessing upadacitinib, an oral selective Janus kinase inhibitor, in patients with nonsegmental vitiligo. We found the VNS to be a valid and reliable global measure that can differentiate between clinically distinct groups and is sensitive to change.


  • Open Access

    Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials

    by Andrew Östör, Filip Van Den Bosch, Kim Papp, Mauro Keiserman, Ricardo Blanco, Angela Crowley, Douglas White, Ana Biljan, Tshepiso Madihlaba, Kyle Carter, et al.

    Introduction The ongoing KEEPsAKE 1 and 2 (KS1; KS2) trials evaluate the efficacy and safety of risankizumab in patients with psoriatic arthritis (PsA) who had an inadequate response to ≥ 1 conventional synthetic disease-modifying antirheumatic drug(s) (csDMARD-IR, KS1&2) and/or 1–2 biologic DMARDs (bDMARD-IR, KS2). Herein, we present week 196 efficacy and safety findings from KS1 and KS2. Methods Patients were randomized 1:1 in a double-blind fashion to receive subcutaneous risankizumab 150 mg or placebo (weeks 0, 4, 16, and 24). All patients received open-label risankizumab at week 28 and every 12 weeks thereafter (i.e., continuous risankizumab, placebo/risankizumab). Assessments included ≥ 20%/50%/70% improvement in PsA symptoms using American College of Rheumatology criteria (ACR20/50/70) and achievement of minimal disease activity (MDA). Results At week 196, 749 patients remained in KS1 and 289 in KS2. In KS1, 57.1% of patients receiving continuous risankizumab and 56.5% receiving placebo/risankizumab achieved ACR20, while 54.5% receiving continuous risankizumab and 50.2% receiving placebo/risankizumab achieved ACR20 in KS2 at week 196. Maintenance of ACR20 achievement in KS1 from week 52 to week 196 was observed for 71.0% of patients receiving continuous risankizumab and 72.7% receiving placebo/risankizumab. The same was observed in KS2 for 68.7% of patients receiving continuous risankizumab and 73.0% receiving placebo/risankizumab. The proportion of patients achieving MDA was 39.6% receiving continuous risankizumab and 35.2% receiving placebo/risankizumab in KS1, while 35.3% of patients receiving continuous risankizumab and 37.4% receiving placebo/risankizumab achieved MDA in KS2 at week 196. In KS1, maintenance of MDA at week 196 from week 52 was achieved by 72.8% of patients receiving continuous risankizumab and 72.2% receiving placebo/risankizumab. In KS2, 77.0% of patients receiving continuous risankizumab and 70.3% receiving placebo/risankizumab achieved the same. No new safety signals were reported. Conclusions Risankizumab demonstrated durable efficacy and safety at week 196 in KS1 and KS2. Trial Registration KS1: ClinicalTrials.gov, NCT03675308; KS2: ClinicalTrials.gov, NCT03671148.


  • Open Access

    Eficácia e segurança do risanquizumabe versus metotrexato em pacientes com psoríase em placas moderada a grave: Resultados do IMMbrace, estudo randomizado, duplo‐cego, de fase 3 com período de extensão aberto no Brasil

    by Tania F. Cestari, Cacilda da Silva Souza, Luna Azulay‐Abulafia, Ricardo Romiti, André V.E. Carvalho, Caio César Silva de Castro, Silvio Alencar Marques, João Roberto Antonio, Lincoln Fabrício, Ahmed M. Soliman, et al.

  • Open Access

    Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil

    by Tania F. Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, Ricardo Romiti, André V.E. Carvalho, Caio César Silva de Castro, Sílvio Alencar Marques, João Roberto Antonio, Lincoln Fabrício, Ahmed M. Soliman, et al.


  • Open Access

    Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

    by April W. Armstrong, Ahmed M. Soliman, Paolo Gisondi, Siran Fang, Manish Patel, Bruce Strober

    Introduction Despite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO. Our objective was to assess the comparative clinical effectiveness of risankizumab and deucravacitinib in patients with moderate-to-severe PsO. Methods This placebo-anchored matching-adjusted indirect comparison (MAIC) analysis utilized data from UltIMMa-1/2 risankizumab and POETYK PSO-1/2 deucravacitinib trials. Individual patient data from UltiMMA-1/2 were weighted via propensity score to match POETYK PSO-1/2 published summary data. Rate differences between risankizumab and deucravacitinib were assessed for Psoriasis Area and Severity Index (PASI) 75/90/100, the Static Physician Global Assessment (sPGA = 0 or 0/1), and the Dermatology Life Quality Index (DLQI) 0/1. Results At 16 weeks, risankizumab-treated patients demonstrated statistically significantly higher rates of skin clearance and greater improvement in quality of life (QoL) compared to those treated with deucravacitinib. Across all outcomes, risankizumab demonstrated a lower number needed to treat compared to deucravacitinib. Limitations are potential bias due to unobserved/unmeasurable differences and limited generalizability of the results. Conclusions This indirect comparison demonstrates that risankizumab has higher rates of skin clearance and greater improvements in QoL than deucravacitinib. This study will help inform healthcare providers in their treatment and management strategy of PsO.


  • Open Access

    Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location

    by David Rosmarin, Ahmed M. Soliman, James Piercy, Simran Marwaha, Peter Anderson, Heidi S. Camp

    Introduction Vitiligo was historically regarded as a cosmetic disorder; however, it is an autoimmune disease. As a visible condition, it affects patient well-being. We assessed the impact of disease severity, lesion location, and body surface area (BSA) affected on patient health-related quality of life (HRQoL). Methods Retrospective data were from the Adelphi Real World Vitiligo Disease Specific Programme: a cross-sectional survey of physicians and their patients with vitiligo (10/2021–07/2022). Patient-reported outcomes were assessed by the Vitiligo-Specific Quality of Life Instrument (VitiQoL), Hospital Anxiety and Depression Scale (HADS), and EQ-5D-5L. The Work Productivity and Impairment Questionnaire (WPAI) questionnaire was used to assess disease-related impairment of daily activities. Data were stratified by physician-reported disease severity, presence/absence of vitiligo on the face, and BSA percentage affected. Results In total, 1388 patients were included. Mean (SD) VitiQoL, HADS depression, and anxiety scores were higher for those with severe disease [40.5 (26.1), 5.2 (4.4), and 6.8 (4.7)] than those with mild [24.8 (18.8), 3.6 (3.8), 4.2 (3.8)] or moderate [27.1 (22.6), 3.8 (4.5), 4.3 (4.4)] disease. Patients with face affected reported higher VitiQoL [30.0 (22.3) versus 23.2 (19.3)], and HADS scores [depression, 4.3 (4.3) versus 3.2 (3.9); anxiety, 5.0 (4.3) versus 3.8 (3.9)] than those without. Patients with ≥ 5% BSA affected had higher VitiQoL, depression and anxiety scores [27.9 (21.8), 4.0 (4.4), and 4.5 (4.2)] than those with 0–5% [24.6 (19.7), 3.4 (3.7), and 4.3 (4.1)]. Patients with severe vitiligo, facial lesions, or ≥ 5% BSA reported higher activity impairment. Mean EQ-5D-5L-utility score was approximately 0.9 regardless of disease severity or total BSA affected. Conclusions These data demonstrate the impact disease severity can have on HRQoL and daily activities for patients with vitiligo. Lesions that are more severe, on the face, or covering a greater BSA are more often associated with poorer outcomes and activity impairment. These data also highlight the potential insensitivity of commonly used HRQoL measures and a need for more sensitive disease-specific measures.


  • Open Access

    Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan

    by Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, Ryuta Sakuma, Andreas Pinter, Matthew Davis, Dominic Nunag, Marric Buessing, Luis Puig, Shinichi Imafuku

    Patients receiving interleukin (IL)‐inhibiting biologics for moderate‐to‐severe psoriasis (PsO) may be treated with escalated doses to optimize outcomes. This study evaluated escalation prevalence in a Japanese claims analysis of patients with PsO diagnosis preceding IL‐inhibiting biologic treatment and ≥1 post‐induction maintenance claim (index date) with sufficient data availability from January 2014 to May 2022. Patients with non‐persistence were excluded. Expected daily dose (EDD) was calculated as the recommended maintenance dose divided by the treatment interval. Dose escalation was defined as ≥2 claims showing a ≥20% increase in the observed average daily dose (ADD) over the EDD (with sensitivities requiring ≥1 claim and ≥30%). Significant differences were tested using multivariable regressions. The study included 982 unique patients treated with brodalumab (BRO; n = 104), guselkumab (GUS; n = 207), ixekizumab (IXE; n = 159), risankizumab (RIS; n = 135), secukinumab (SEC; n = 215) and ustekinumab (UST; n = 196). Within 12 months, dose escalation was observed for all IL‐inhibiting biologics other than GUS and RIS: 44.4% for UST, 37.2% for IXE, 3.4% for SEC and 1.4% for BRO. In multivariable‐adjusted analyses, odds of dose escalation were significantly lower for all products relative to UST. In sensitivities, escalation was observed for all products except RIS.